Revenue
2023
2024
2025
Heartflow, Inc. (HTFL)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $176.0M | $125.8M | $87.2M |
| Gross profit | $135.2M | $94.4M | $58.1M |
| Research & development | $64.9M | $43.5M | $35.9M |
| Operating expenses | $199.3M | $155.7M | $131.0M |
| Operating income | −$64.1M | −$61.2M | −$72.9M |
| EBITDAderived | −$58.6M | −$55.9M | −$68.2M |
| Net income | −$116.8M | −$96.4M | −$95.7M |
| Basic EPSper diluted share | -$3.17 | -$17.98 | -$25.32 |
| Diluted EPSper diluted share | -$3.17 | -$17.98 | -$25.32 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | Farquhar John C.M.Chief Executive Officer | SellCommon Stock | 38.9K | $35.00 | $1.36M | 457.9K |
| Jun 10, 2026Form 4 · 10b5-1 | Farquhar John C.M.Chief Executive Officer | SellCommon Stock | 22.6K | $28.50 | $643.0K | 496.8K |
| May 18, 2026Form 4 · 10b5-1 | Rogers CampbellChief Medical Officer | SellCommon Stock | 9.2K | $28.34 | $261.3K | 78.7K |
| May 11, 2026Form 4 · 10b5-1 | Farquhar John C.M.Chief Executive Officer | SellCommon Stock | 22.6K | $29.12 | $657.0K | 519.4K |
| Apr 30, 2026Form 4 | Bain Capital Life Sciences III General Partner, LLC +4TenPercentOwner | SellCommon Stock · indirect | 56.2K | $30.05 | $1.69M | 8.45M |